REG - Arecor Therapeutics - Exercise of options and PDMR dealing

Arecor TherapeuticsAnnouncement

08/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221108:nRSH6008Fa&default-theme=true

RNS Number : 6008F  Arecor Therapeutics PLC  08 November 2022

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

 

Exercise of rollover options, PDMR dealing and Total Voting Rights

 

Cambridge, UK, 8 November 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier
lives, announces that it has issued and allotted 131,433 new Ordinary Shares
of 1 pence each in the share capital of the Company following an exercise of
options on 7 November 2022 at an exercise price of 1 pence per Ordinary Share.
The options exercised were part of the rollover of share options previously
granted under the historic Arecor Limited EMI Share Option Plan 2018 ("Option
Rollover"). Details of the Option Rollover are set out in the Company's
Admission Document.

 

Included in the exercise of options were options over 109,958 ordinary shares
held by Directors/PDMRs of the Company as detailed in the table below:

 

 Director/ PDMR         Position                               Existing interest in Ordinary Shares  Number of Options over Ordinary Shares exercised  Resultant interest in Ordinary Shares  Rollover options remaining after exercise
 David Gerring          VP, Development                        151,292                               3,334                                             154,626                                0
 Sarah Howell           Chief Executive Officer                847,072                               20,666                                            867,738                                0
 Jan Jezek              Chief Scientific Officer               404,474                               3,334                                             407,808                                0
 Fiona Lawrence         VP, Clinical & Regulatory Affairs      70,334                                1,666                                             72,000                                 0
 Susan Lowther          Chief Financial Officer                139,849                               62,000                                            201,849                                0
 James MacDonald-Clink  VP, Business Development               25,000                                18,958                                            43,958                                 16,042

 

 

Admission

Following the above transactions, application has been made for the 131,433
new Ordinary Shares to be admitted to trading on AIM ("Admission") and
dealings are expected to commence on, or around, 11 November 2022. The new
Ordinary Shares will rank pari passu with the Company's existing Ordinary
Shares.

The total number of Ordinary Shares in issue following Admission will be
30,618,183 accordingly, the figure of 30,618,183 may be used by shareholders
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest in the
Company under the FCA's Disclosure and Transparency Rules.

 

 

 

For further information, please contact:

 

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)

 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:sarah.howell@arecor.com)

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited                      Tel: +44 (0) 20 7886 2500

 (NOMAD and Broker)

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray          Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat ™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com/)

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

       Details of the person discharging managerial responsibilities/person closely
       associated
 a)    Name:                                                         a)  David Gerring

                                                                     b)  Sarah Howell

                                                                     c)  Jan Jezek

                                                                     d)  Fiona Lawrence

                                                                     e)  Susan Lowther

                                                                     f)  James MacDonald-Clink

 2.    Reason for the notification
 a)    Position/status:                                              a)  VP, Development

                                                                     b)  Chief Executive Officer

                                                                     c)  Chief Scientific Officer

                                                                     d)  VP, Clinical & Regulatory Affairs

                                                                     e)  Chief Financial Officer

                                                                     f)  VP, Business Development

 b)    Initial notification/Amendment:                               Initial notification
 3.    Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name:                                                         Arecor Therapeutics plc
 b)    LEI:                                                          98450093D12I3A8DDD58
 4.    Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the financial instrument, type of instrument:  Ordinary shares of 1 pence each

       Identification code:                                          GB00BMWLM973
 b)    Nature of the transaction:                                    Exercise of options over ordinary shares
 c)    Price(s) and volume(s):

Price(s)   Volume(s)
                                                                     a) £0.01   a) 3,334
                                                                     b) £0.01   b) 20,666
                                                                     c) £0.01   c) 3,334
                                                                     d) £0.01   d) 1,666
                                                                     e) £0.01   e) 62,000
                                                                     f) £0.01   f) 18,958

 

 d)    Aggregated information:

       · Aggregated volume:                                           109,958

       · Price:                                                      £0.01
 e)    Date of the transaction:                                      07 November 2022
 f)    Place of the transaction:                                     London Stock Exchange, AIM Market (XLON)

 

 

d)

Aggregated information:

· Aggregated volume:

· Price:

 

 109,958

£0.01

e)

Date of the transaction:

07 November 2022

f)

Place of the transaction:

London Stock Exchange, AIM Market (XLON)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDDBDBRGGDGDR